U.S. Markets closed

Bioventus Inc. (BVS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.75+0.85 (+5.70%)
At close: 4:00PM EDT

15.75 0.00 (0.00%)
After hours: 4:38PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.90
Open15.11
Bid15.75 x 1200
Ask15.77 x 800
Day's Range14.72 - 15.94
52 Week Range10.74 - 19.51
Volume182,336
Avg. Volume424,808
Market Cap894.998M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.33
  • Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System
    GlobeNewswire

    Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System

    Fourteen Facilities Across the US Receive Multidisciplinary Therapy SolutionVALENCIA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the first commercial shipments of the Bioness Integrated Therapy System (BITS) for Balance. BITS® Balance accelerates the value of the BITS platform by adding over 40 new programs and assessments, leveraging proprietary motion sensing technology on any easy to use, adjustable balance platform. From independent physical therapy practices, to regional medical centers, and national providers, the technology will aid clinicians in challenging, assessing, and tracking patients’ balance, stability, and strength, ultimately maximizing therapy outcomes. “This improvement to BITS Balance will further aid patients in their rehabilitation journey, and make it easier for therapists to provide exceptional care,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Our dedicated clinical partners all have the same goal in mind, to improve patient outcomes.” New research continues to amplify the increased need for rehabilitation, bringing it to the forefront of patient care. According to a recent study published in American Physical Therapy Association, one in three people worldwide had a condition that rehabilitation could have helped, from both a cognitive and physical level.1 It is important to note that with each patient and case, the situation is unique and the needs are particular. BITS Balance was designed to create personalized training sessions for every level of mobility, and reduce the time needed to administer tests and analyze results, saving valuable time, while providing critical insight on patient outcomes and progression. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. With the recent acquisition of Bioness, Inc., Bioventus expanded product offerings now include products for acute and chronic pain, central nervous system disorders including stroke and orthopedic injuries. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, www.bioness.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. BITS®, Bioness®, are trademarks of Bioness Inc. Individual results may vary. Patients are advised to consult with a qualified healthcare professional to determine if this product is right for them. Important Safety Information and Risks: For Indications for Use, Warnings, Precautions, and other safety information please refer to www.bionesstherapy.com/safety. Also available in the BITS Clinician's Guide online HERE. Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2030; DOI: https://doi.org/10.1016/S0140-6736(20)32340-0 Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning the expected benefits and market opportunities of the BITS Balance system, . In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release include, but are not limited to, statements about the adverse impacts on our business as a result of the COVID-19 pandemic; our dependence on a limited number of products; our ability to develop, acquire and commercialize new products, line extensions or expanded indications; the continued and future acceptance of our existing portfolio of products and any new products, line extensions or expanded indications by physicians, patients, third-party payers and others in the medical community; our ability to differentiate the hyaluronic acid (“HA”) viscosupplementation therapies we own or distribute from alternative therapies for the treatment of osteoarthritic; the proposed down-classification of non-invasive bone growth stimulators, including our Exogen system, by the U.S. Food and Drug Administration (“FDA”); our ability to achieve and maintain adequate levels of coverage and/or reimbursement for our products, the procedures using our products, or any future products we may seek to commercialize; our ability to complete acquisitions or successfully integrate new businesses, products or technologies in a cost-effective and non-disruptive manner; competition against other companies; the negative impact on our ability to market our HA products due to the reclassification of HA products from medical devices to drugs in the United States by the FDA; our ability to attract, retain and motivate our senior management and qualified personnel; our ability to continue to research, develop and manufacture our products if our facilities are damaged or become inoperable; failure to comply with the extensive government regulations related to our products and operations; enforcement actions if we engage in improper claims submission practices or in improper marketing or promotion of our products; the FDA regulatory process and our ability to obtain and maintain required regulatory clearances and approvals; failure to comply with the government regulations that apply to our human cells, tissues and cellular or tissue-based products; the clinical studies of any of our future products that do not product results necessary to support regulatory clearance or approval in the United States or elsewhere; and the other risks identified in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission (“SEC”), including Bioventus’ Annual Report on Form 10-K for the period ended December 31, 2020, as such factors may be updated from time to time in Bioventus’ other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’ website at ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business. Media Contact:Thomas Hill919-474-6715thomas.hill@bioventusglobal.com Investor Inquiries:Mike Piccinino, CFA, IRCWestwicke/ICRinvestor.relations@bioventus.com

  • Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021
    GlobeNewswire

    Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021

    DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fiscal year 2021 financial results will be released after the market closes on Wednesday, May 12, 2021. Management will host a conference call to discuss its financial results and provide a business update, with a question and answer session, at 5:00 p.m. Eastern Time on May 12, 2021. Those who would like to participate may dial 844-945-2085 (442-268-1266 for international callers) and provide access code 8976184. A live webcast of the call and any accompanying materials will also be provided on the investor relations section of the Company's website at https://ir.bioventus.com/. The webcast will be archived on the Company’s website at https://ir.bioventus.com/ and available for replay until May 12, 2022. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. With the recent acquisition of Bioness,Inc, Bioventus expanded product offerings with the Bioness products include offerings for acute and chronic pain, central nervous system disorders including stroke and orthopedic injuries. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, www.bioness.com and follow the company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. CONTACT: Media Contact: Thomas Hill 919-474-6715 thomas.hill@bioventusglobal.com Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke/ICR Investor.relations@bioventus.com

  • Bioventus Snaps Up Bioness; Street Remains Bullish
    SmarterAnalyst

    Bioventus Snaps Up Bioness; Street Remains Bullish

    Bioventus Inc. has acquired medical devices provider Bioness Inc. for a total consideration of $110 million. This includes an up-front payment of $45 million and milestone payments of up to $65 million. Bioventus (BVS) CEO, Ken Reali, said, “We aim to accelerate Bioness’ revenue growth by leveraging our existing global network of approximately 300 sales representatives calling on orthopaedic, pain and podiatric physicians as well as expanding market access and reimbursement processing capabilities.” Bioventus is paying the up-front consideration from cash on hand. The transaction includes Bioness’ complete product portfolio along with its research and development pipeline. Bioness’ products include electrical stimulation exoskeletal devices, robotic gait and fall safety systems and interactive software learning and recovery assessment platforms. Bioventus expects this acquisition to be revenue accretive and boost its multi-year revenue growth. It sees revenue for 2021 to be in the range of $390 million to $402 million including the revenue impact of the Bioness acquisition. (See Bioventus stock analysis on TipRanks) On March 26, Canaccord Genuity analyst Kyle Rose reiterated a Buy rating on the stock and maintained a $23 price target (49% upside potential). Commenting on the company’s 2021 guidance, Rose said, “2021 guidance bracketed expectations and offers multiple routes to upside across each of its three business units. We see continued momentum as the company works through what we hope to be the late innings of the COVID-19 pandemic and transitions to ‘business as usual’ in H2/21.” Rose added, “We believe Bioventus has the assets, scale, clinical differentiation, and pipeline to break through as a classic small-cap medtech execution story.” Turning to rest of the Street, the stock has a Strong Buy consensus rating alongside an average analyst price target of $19.25 (24.7% upside potential) based on 4 unanimous Buys. Related News: MSG Entertainment Inks Deal To Buy MSG Networks; Shares Tank 10% Canoo’s 4Q Loss Improves On Electric Vehicles Strength Hartford Walks Away From Chubb’s Merger Offer More recent articles from Smarter Analyst: Hyatt Plans Major Footprint Expansion In India Vipshop To Buy Back $500M In Stock; Shares Pop 9% Bloom Energy Deploys Solid Oxide Fuel Cells; Street Sees 38.6% Upside Equillium Reports Positive Itolizumab Phase 1 Data; Shares Rise 7.6% After-Hours